Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

Immuron Limited (ASX: IMC) development candidate IMM‑529 — an orally delivered, bovine colostrum-derived antibody therapy targeting Clostridioides difficile infection (CDI) — has had its Investigational New Drug (IND) application approved by the U.S. Food & Drug Administration, authorising a Phase 2 randomized, double-blind, placebo-controlled trial in Australia with up to 60 adult participants.

FDA Clears Immuron’s IMM-529 For Clinical Testing in C difficile; Phase 2 Set to Begin in Australia